International Journal of Radiation Oncology*Biology*Physics
Brief communicationThe management of desmoid tumors☆
References (38)
- et al.
Role of brachytherapy in the management of desmoid tumors
Int. J. Radiat. Oncol. Biol. Phys.
(1986) - et al.
Desmoid tumors of the chest wall
Chest
(1978) - et al.
Chemotherapy of locally aggressive head and neck tumors in the pediatric age group
Am. J. Surg.
(1982) - et al.
Radiation therapy in the treatment of aggressive fibromatosis
Int. J. Radiat. Oncol. Biol. Phys.
(1981) - et al.
Estrogen and antiestrogen binding sites in desmoid tumors
Eur. J. Cancer Clin. Oncol.
(1986) - et al.
Desmoid tumors of the head and neck
Am. J. Surg.
(1966) - et al.
Radiation therapy for aggressive fibromatosis
J. Bone Joint Surg.
(1991) - et al.
Extra-abdominal desmoid tumours: Their differential diagnosis and treatment
Arch. Pathol.
(1948) - et al.
A recurrent pelvic desmoid tumor successfully treated with Tamoxifen
Cancer
(1991) Radiation dose and response of desmoid tumors
Int. J. Radiat. Oncol. Biol. Phys.
(1990)
Musculoaponeurotic fibromatosis, a report of 28 cases and review of the literature
Clin. Orthol Rel. Research
Extra-abdominal desmoids: A clinicopathologic study
Annals of Surgery
Musculo-aponeurotic fibromatosis of the shoulder girdle (extra-abdominal desmoid). Analysis of thirty cases followed up for ten or more years
Cancer
Soft tissue tumors
Neoplastic Diseases
Pediatric Radiation Oncology
et al.Pediatric Radiation Oncology
Spontaneous regression of a desmoid tumor
J. Bone Joint Surg.
Nonparametric estimation from incomplete observation
J. Am. Stat. Assoc.
The role of radiotherapy in the treatment of desmoid tumors
Radiother. Oncol.
Cited by (110)
Soft Tissue Tumors of the Abdomen and Retroperitoneum
2020, Surgical Clinics of North AmericaCitation Excerpt :In the postoperative setting, radiation therapy is not recommended, given that there is no conclusive advantage.91,92 Patients with disease unamenable to surgery may benefit from consultation with a sarcoma medical oncologist or radiation oncologist.93 To determine the applicability and safety of an initial observation strategy, the initiation of medical therapy, or the consideration for resection, the international collaborative of the Desmoid Tumor Working Group recommends coordinated management with a multidisciplinary team of sarcoma clinicians at the time of diagnosis.79,90,94
The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients
2020, European Journal of CancerCitation Excerpt :This modality can be a valid alternative to surgery and can be used if medical therapies are not available or not active. Summarising the data comparing radiotherapy to surgery [33]; “very low” according to GRADE, the anticipated absolute risk of progressive disease after radiotherapy alone is 19% versus 29% after surgery alone, however, not being statistically significant (RR 0.65, 95% CI 0.35–1.22). In summary, when active management for DT is required, surgery as first-line therapy can be considered, provided expected surgical morbidity is limited.
Bone Sarcomas and Desmoids
2020, Hematology/Oncology Clinics of North AmericaConservative management of desmoid tumors is safe and effective
2016, Journal of Surgical ResearchCitation Excerpt :Although desmoid tumors do not metastasize, they can be locally infiltrative causing symptoms, such as pain and neuropathy, and in their most severe forms may be limb threatening.2 Historically, the standard treatment approach for desmoid tumors was surgical resection.1,3,4 However, because of the infiltrative nature of these tumors, many series have reported high rates of local recurrence after surgical resection, ranging from 20% to 50%.5-7
Extra-abdominal desmoid fibromatosis: A review of management, current guidance and unanswered questions
2016, European Journal of Surgical OncologyMusculoskeletal Disorders
2023, Medical Radiology
- ☆
Presented at the 34th Annual Meetings of the American Society for Therapeutic Radiology and Oncology (ASTRO) Meeting, San Diego, CA, 8–13 November 1992.
- ∗
Dept. of Radiation Oncology.
- †
Dept. of Pathology.